Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

SAN DIEGO, Nov. 7, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the third quarter of 2011 and discussed recent business progress.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The past few months highlight the progress at Halozyme on all fronts, with positive results from our Insulin programs, Roche's Herceptin SC Phase 3 study and additional regulatory submissions for Baxter's HyQ program," said Gregory I. Frost, Ph.D., Halozyme's President and CEO. "The initiation of trials with PEGPH20 and HTI-501, two first in class biologics developed by Halozyme, further support our growth strategy balanced by partnered revenue."

Recent Highlights

  • Announced positive results from the Phase 3 HannaH trial, conducted by Roche, showing that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), demonstrated comparable efficacy to Herceptin given as an intravenous (IV) infusion. HannaH is a Phase 3, open-label trial involving 596 women with HER2-positive early breast cancer and was designed to compare trastuzumab concentration in the blood, efficacy and safety of Herceptin SC to that of Herceptin IV. The trial met its co-primary PK and efficacy endpoints of pathologic complete response and trastuzumab concentration in the blood (serum concentrations) and efficacy.  No new side effects were seen compared to previous trials with Herceptin IV.
  • Presented positive results from
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
    (Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
    (Date:7/31/2014)... 2014 “Rapid technological advances will ... U.S., increasing unemployment, depressing American consumer spending and ... a Catch 22—we need automated manufacturing if we ... jobs,” says economist and corporate relocation expert Dr. ... 10 Pro-Business States for 2014, co-published with the ...
    (Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 ... ) finds itself flush with innovative adult stem cell ... patents and has three additional patent applications ... Office. , The patented inventions address two of the ... and regenerative medicine. Adult stem cells are difficult ...
    Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3
    ... Leading US Spine Centers Committed to the IEP,s ... 24 Magnifi Group, considered by,many industry observers ... within the medical device and pharmaceutical industries,announced here ... annual,meeting, its intent to organize and develop real-time ...
    ... Efforts to ... MENTOR, Ohio, Oct. 24 STERIS Corporation,(NYSE: STE ... its,VaproSure(TM) Room Sterilizer from several U.S. hospitals. The VaproSure,Room Sterilizer ... kind for the healthcare market. Since being introduced in,June of ...
    ... Cell Therapeutics,Inc. (CTI) (Nasdaq and MTAX: ... annual AACR-NCI-EORTC Symposium show its bis-platinate drug,candidates, ... currently,marketed platinum agents carboplatin, cisplatin and oxaliplatin. ... late 2008. "Bis-platinates represent a promising ...
    Cached Biology Technology:Magnifi Group Demonstrates Industry's First Interactive Educational Program (IEP) for Spine Fellows 2Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 2Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 3Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 4Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 5Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 6First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3
    (Date:7/31/2014)... from shale rock has increased by more than ... not fully understand the industry,s effects on nature ... journal Frontiers in Ecology and the Environment ... outpace scientific examination, a team of eight conservation ... University, concluded that determining the environmental impact of ...
    (Date:7/31/2014)... New research, supported by the National Science Foundation ... permafrost uniformly accelerates atmospheric warming, indicating instead that ... they emit into the atmosphere. , The ... Nature , focuses on thermokarst lakes, which occur ... fill with melted fresh water, converting what was ...
    (Date:7/31/2014)... biomass burning burning forests to create agricultural ... agriculture and wildfires figures into both climate ... release of a new study by Stanford University ... the degree of that contribution had never been ... paper published July 30 in the Journal ...
    Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3Certain Arctic lakes store more greenhouse gases than they release 2Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4
    ... the world, this week,s edition of Chemical & Engineering ... on the jobs situation for chemists -- whose work directly ... chemical industry in the United States alone a $674 billion ... American Chemical Society, the world,s largest scientific society. ...
    ... life scientists have identified a gene that slows the aging ... activated a gene called PGC-1, which increases the activity of ... growth and tell cells when to live and die. ... in different cells and tissues of the fly and asked ...
    ... tree outside Oak Ridge National Laboratory researcher Pratul Agarwal,s ... may ultimately lead to drugs with fewer side effects, ... breeze causes leaves, branches and ultimately the tree to ... of chemical processes that have a ripple effect necessary ...
    Cached Biology News:UCLA biologists slow the aging process in fruit flies 2UCLA biologists slow the aging process in fruit flies 3ORNL fundamental discovery casts enzymes in new light 2
    MOUSE ANTI POLY (ADP-RIBOSE) Immunogen: Purified poly (ADP-ribose) polymer, 10-50 unit chain length...
    ... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
    The Protein Kinase Factsbooks (2 Volume Set)...
    All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
    Biology Products: